Smith & Nephew (SN) Earns Hold Rating from Deutsche Bank

Deutsche Bank reaffirmed their hold rating on shares of Smith & Nephew (LON:SN) in a report issued on Friday.

Several other brokerages have also commented on SN. Morgan Stanley raised shares of Smith & Nephew to an overweight rating and upped their price target for the stock from GBX 1,457 ($19.04) to GBX 1,692 ($22.11) in a research report on Monday, December 10th. UBS Group reaffirmed a neutral rating on shares of Smith & Nephew in a research report on Friday, October 26th. JPMorgan Chase & Co. reaffirmed a neutral rating and set a GBX 1,477 ($19.30) price target on shares of Smith & Nephew in a research report on Tuesday, January 8th. Berenberg Bank upped their price target on shares of Smith & Nephew from GBX 1,370 ($17.90) to GBX 1,475 ($19.27) and gave the stock a hold rating in a research report on Friday, November 2nd. Finally, HSBC lowered shares of Smith & Nephew to a hold rating and upped their price target for the stock from GBX 1,400 ($18.29) to GBX 1,500 ($19.60) in a research report on Tuesday, October 16th. Nine equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The company has an average rating of Hold and a consensus target price of GBX 1,479.36 ($19.33).

Shares of SN stock opened at GBX 1,469.50 ($19.20) on Friday. Smith & Nephew has a one year low of GBX 1,173 ($15.33) and a one year high of GBX 1,442 ($18.84).

The firm also recently disclosed a dividend, which will be paid on Wednesday, May 8th. Stockholders of record on Thursday, April 4th will be given a $0.22 dividend. The ex-dividend date of this dividend is Thursday, April 4th. This represents a dividend yield of 1.1%. This is a positive change from Smith & Nephew’s previous dividend of $0.14.

Smith & Nephew Company Profile

Smith & Nephew plc designs, develops, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder.

Further Reading: Do investors pay a separate front-end load every time they buy additional shares?

Analyst Recommendations for Smith & Nephew (LON:SN)

Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply